Heidelberg Pharma AG (LON:0QW5)

Market Cap	84.94M -33.8%
Revenue (ttm)	7.99M +206.8%
Net Income	-25.63M
EPS	-0.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9
Open	2.170
Previous Close	2.190
Day's Range	2.170 - 2.170
52-Week Range	2.020 - 3.310
Beta	0.78
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 24, 2027

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company’s lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 33
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QW5

Financial Performance

In fiscal year 2025, Heidelberg Pharma AG's revenue was 1.46 million, a decrease of -78.72% compared to the previous year's 6.85 million. Losses were -42.28 million, 118.1% more than in 2024.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error